Efficacy and Determinant Factors of Linezolid Containing Regimens in the Treatment of DR - TB Patients at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia, 2023 A Retrospective Study

Background: A synthetic oxazolidinone antimicrobial medication called Linezolid is used to treat patients who are resistant to multiple drugs. Few studies have been done regarding the effectiveness of Linezolid-containing regimens in both developing and developed nations. This study aimed to determine the Efficacy and determinant factors of linezolid-containing regimens in the treatment of DR - TB Patients. Methods: An institution-based cross-sectional study design was conducted using SPSS version 26, and multivariable binary logistic regression analysis was used. Result: out of 345 patients that visited the outpatient clinic, 205 (59.4%) were males, and 126(36.5%) were between 30-39 years. MDR TB Patients' linezolid-containing regimen treatment efficacy success rate is 280(81.2%). MDR TB Patient Previously Treated TB by First Line Drug [AOR= 5.823(3.761-7.341)]. MDR TB Patient Previously Treated TB by First Line and treatment completed [AOR=2.351(1.34-3.214))], the adverse effect [AOR 0.842(0.674-2.431], tolerability of linezolid [AOR =2.543(2.41-4.532)] was significantly associated with linezolid containing regimen treatment efficacy rate. Conclusion: Linezolid-containing regimens have good efficacy and good treatment outcomes for DR-TB patients. The findings showed that Linezolid is a good choice for treating DR-TB, although patients ought to be monitored closely for the incidence of adverse effects.